inflarx nv shares were down 156 to 420 in midday trading on wednesday after the companys underwritten public offering of 94 million shares priced at 425 per ordinary share the clinicalstage biopharmaceutical company based in germany said it plans to use proceeds from the offering to support the development of vilobelimab an injection that treats covid19 as well as other general research and development expenses and investments the offering is expected to close on april 14 shares are up 417 since the start of the year and have risen about 151 in the last 12 months inflarxs stock surged earlier this month after gohibic a monoclonal antihuman complement factor c5a antibody it is developing was granted emergency use authorization by the us food and drug administration